Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jul 12;9(7):779.
doi: 10.3390/vaccines9070779.

Neutralizing Activity of Sera from Sputnik V-Vaccinated People against Variants of Concern (VOC: B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.617.3) and Moscow Endemic SARS-CoV-2 Variants

Vladimir A Gushchin  1   2 , Inna V Dolzhikova  1 , Alexey M Shchetinin  1 , Alina S Odintsova  1 , Andrei E Siniavin  1   3 , Maria A Nikiforova  1 , Andrei A Pochtovyi  1   2 , Elena V Shidlovskaya  1 , Nadezhda A Kuznetsova  1 , Olga A Burgasova  1   4   5 , Liudmila V Kolobukhina  1   4 , Anna A Iliukhina  1 , Anna V Kovyrshina  1 , Andrey G Botikov  1 , Aleksandra V Kuzina  1 , Daria M Grousova  1 , Amir I Tukhvatulin  1 , Dmitry V Shcheblyakov  1 , Olga V Zubkova  1 , Oksana V Karpova  4 , Olga L Voronina  1 , Natalia N Ryzhova  1 , Ekaterina I Aksenova  1 , Marina S Kunda  1 , Dmitry A Lioznov  6   7 , Daria M Danilenko  6 , Andrey B Komissarov  6 , Artem P Tkachuck  1 , Denis Y Logunov  1 , Alexander L Gintsburg  1   8
Affiliations

Neutralizing Activity of Sera from Sputnik V-Vaccinated People against Variants of Concern (VOC: B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.617.3) and Moscow Endemic SARS-CoV-2 Variants

Vladimir A Gushchin et al. Vaccines (Basel). .

Abstract

Since the beginning of the 2021 year, all the main six vaccines against COVID-19 have been used in mass vaccination companies around the world. Virus neutralization and epidemiological efficacy drop obtained for several vaccines against the B.1.1.7, B.1.351 P.1, and B.1.617 genotypes are of concern. There is a growing number of reports on mutations in receptor-binding domain (RBD) increasing the transmissibility of the virus and escaping the neutralizing effect of antibodies. The Sputnik V vaccine is currently approved for use in more than 66 countries but its activity against variants of concern (VOC) is not extensively studied yet. Virus-neutralizing activity (VNA) of sera obtained from people vaccinated with Sputnik V in relation to internationally relevant genetic lineages B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.617.3 and Moscow endemic variants B.1.1.141 (T385I) and B.1.1.317 (S477N, A522S) with mutations in the RBD domain has been assessed. The data obtained indicate no significant differences in VNA against B.1.1.7, B.1.617.3 and local genetic lineages B.1.1.141 (T385I), B.1.1.317 (S477N, A522S) with RBD mutations. For the B.1.351, P.1, and B.1.617.2 statistically significant 3.1-, 2.8-, and 2.5-fold, respectively, VNA reduction was observed. Notably, this decrease is lower than that reported in publications for other vaccines. However, a direct comparative study is necessary for a conclusion. Thus, sera from "Sputnik V"-vaccinated retain neutralizing activity against VOC B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.617.3 as well as local genetic lineages B.1.1.141 and B.1.1.317 circulating in Moscow.

Keywords: COVID-19; SARS-CoV-2; Sputnik V; VOC; vaccine; virus neutralizing activity.

PubMed Disclaimer

Conflict of interest statement

I.V.D., A.G.B., D.M.G., A.I.T., D.V.S., O.V.Z., D.Y.L. and A.L.G. report patents for a Sputnik V immunobiological expression vector, pharmaceutical agent, and its method of use to prevent COVID-19. All other authors declare no competing interests.

Figures

Figure 1
Figure 1
SARS-CoV-2 genetic lineages distribution in Russia. Data were collected from GISAID and visualized to represent 20 most frequent lineages in Russia, PANGOLIN nomenclature.
Figure 2
Figure 2
Most common RBD mutations in Russian SARS-CoV-2 variants frequencies of individual mutations according to GISAID data (solid lines) and RBD fragment sequencing data obtained in the current study (dashed lines).
Figure 3
Figure 3
Serum neutralization titers against variants of SARS-CoV-2. The upper graphs show violin plots for serum samples, the lower graphs indicate the individual VNT changes. Geometric mean and 95% CI and p-value (Wilcoxon test) is noted on upper graphs. Number of used serum samples is noted on lower graphs.
See this image and copyright information in PMC

References

    1. Logunov D.Y., Dolzhikova I.V., Shcheblyakov D.V., Tukhvatulin A.I., Zubkova O.V., Dzharullaeva A.S., Kovyrshina A.V., Lubenets N.L., Grousova D.M., Erokhova A.S., et al. Safety and Efficacy of an rAd26 and rAd5 Vector-Based Heterologous Prime-Boost COVID-19 Vaccine: An Interim Analysis of a Randomised Controlled Phase 3 Trial in Russia. Lancet. 2021;397:671–681. doi: 10.1016/S0140-6736(21)00234-8. - DOI - PMC - PubMed
    1. Baden L.R., El Sahly H.M., Essink B., Kotloff K., Frey S., Novak R., Diemert D., Spector S.A., Rouphael N., Creech C.B., et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N. Engl. J. Med. 2021;384:403–416. doi: 10.1056/NEJMoa2035389. - DOI - PMC - PubMed
    1. Polack F.P., Thomas S.J., Kitchin N., Absalon J., Gurtman A., Lockhart S., Perez J.L., Marc G.P., Moreira E.D., Zerbini C., et al. Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine. N. Engl. J. Med. 2020;383:2603–2615. doi: 10.1056/NEJMoa2034577. - DOI - PMC - PubMed
    1. Voysey M., Clemens S.A.C., Madhi S.A., Weckx L.Y., Folegatti P.M., Aley P.K., Angus B., Baillie V.L., Barnabas S.L., Bhorat Q.E., et al. Safety and Efficacy of the ChAdOx1 nCoV-19 Vaccine (AZD1222) against SARS-CoV-2: An Interim Analysis of Four Randomised Controlled Trials in Brazil, South Africa, and the UK. Lancet. 2021;397:99–111. doi: 10.1016/S0140-6736(20)32661-1. - DOI - PMC - PubMed
    1. Sadoff J., Gray G., Vandebosch A., Cárdenas V., Shukarev G., Grinsztejn B., Goepfert P.A., Truyers C., Fennema H., Spiessens B., et al. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against COVID-19. N. Engl. J. Med. 2021;10:2187–2201. doi: 10.1056/NEJMoa2101544. - DOI - PMC - PubMed

LinkOut - more resources